Skip to main content
. Author manuscript; available in PMC: 2017 Oct 24.
Published in final edited form as: Nat Nanotechnol. 2017 Apr 24;12(7):648–654. doi: 10.1038/nnano.2017.52

Figure 2. PC7A NP improves antigen delivery and cross-presentation in APCs and stimulates CD8 T cell responses.

Figure 2

a, Quantification of OVA-positive cells in three APC subtypes inside lymph nodes 24 h after subcutaneous injection of AF647-OVA-PC7A NP at the tail base of C57BL/6 mice (n=5). b, Schematic of detection of antigen cross-presentation in BMDCs and CD8+ T cell activation in vitro. c, Quantification of AF647-OVA uptake in BMDCs by flow cytometry after incubation with AF647-OVA alone, AF647-OVA-PC7A NP or AF647-OVA-PD5A NP for 4h. Mean fluorescence intensity (MFI) of AF647-OVA+ cells in BMDCs was determined (n=3). d, Levels of antigen presentation on H-2Kb in BMDCs induced by PC7A or PD5A NP (n=3). e, IFN-γ secretion by OT-I CD8+ T cells after incubating OT-I CD8+ T cells with BMDCs treated with different OVA-NPs (n=3). f, Representative flow dot plots of H-2kb/SIINFEKL tetratmer staining of CD8+ T cells in spleen. g, Percentage of OVA (SIINFEKL) specific CD8+ T cells was measured by flow cytometry (n=4). In a, c–e and g, representative data from three independent experiments are presented as means ± s.e.m.. Statistical significance was calculated by Student’s t-test, ***P<0.001, **P<0.01, *P<0.05. NS, not significant.